Angelman Syndrome

Angelman syndrome (AS, OMIM #105830) is a rare neurodevelopmental disorder with a prevalence of 1:12,000 – 40,000 patients worldwide. Developmental delay appears between 6-12 months, with symptoms like intellectual disability, severe speech impairment, ataxia, and seizures emerging in early childhood. Individuals with AS often exhibit hyperactivity, sleep disturbances, fascination with water, and a happy demeanor with frequent laughter. Management includes supportive therapies (physical, occupational, speech), antiepileptic medications, and behavioral interventions. Despite requiring lifelong support, individuals with AS can lead fulfilling lives with appropriate interventions. More info

Pathogenic mechanisms

The Ube3a gene has been identified as the causative gene of Angelman syndrome. It is paternally imprinted (i.e. silenced) in mature neurons, therefore mutations or absence of the maternal allele result in AS. This gene can be affected in four ways: large deletions in the gene region, inheriting two copies of the gene from one parent (uniparental disomy), imprinting defects, or mutations directly within the Ube3a gene. The UBE3A protein is an E3 ubiquitin ligase, an enzyme that attaches ubiquitin moieties to its targets, labelling them for destruction, altered localization, or to impact their function. Loss of its function therefore results in accumulation of its targets that likely contribute to disease pathogenesis. Abnormalities in Ube3a expression may impact various brain regions involved in motor coordination, cognition, and behaviour. These pathogenic mechanisms underscore the intricate genetic basis of AS and its associated clinical manifestations.

Mouse Models

  • Del(7Herc2-Mkrn3)13FRdni (deletion of the whole PWS region corresponding to PWS deletion Type 1, imported from JAX)
  • Ube3agenedel (deletion of the Ube3a gene)
  • Ube3atm1Alb (deletion of the exon 5 of Ube3a gene)
  • Ube3a enhancer knockout
  • Ube3a-YFP
  • Snhg14 KO
  • Ube3a-sl-BioID2
  • Ube3a-ll-BioID2